AMPK activator 4|cas:2493239-46-4|西域试剂

AMPK activator 4,99.42%

产品编号：Bellancom-131334| CAS NO：2493239-46-4| 分子式：C₂₄H₂₁ClN₂O₃| 分子量：420.89

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-131334	￥2500.00	杭州北京（现货）
Bellancom-131334	￥4500.00	杭州北京（现货）
Bellancom-131334	￥8500.00	杭州北京（现货）
Bellancom-131334	￥13500.00	杭州北京（现货）
Bellancom-131334	￥19500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AMPK activator 4

产品介绍

AMPK activator 4 是一种有效 AMPK 激活剂，并且不抑制线粒体复合物 I。AMPK activator 4 选择性地激活肌肉组织中的 AMPK。AMPK activator 4 剂量依赖性地改善正常小鼠的糖耐量，显著降低 db/db 糖尿病小鼠的空腹血糖水平和改善胰岛素抵抗。具有降血糖作用。

生物活性

AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect.

体外研究

AMPK activator 4 (compound B10) (0-20 μM; 12-24 hours) induces phosphorylation of AMPK and its downstream protein ACC.
AMPK activator 4-mediated AMPK phosphorylation requires LKB1.
AMPK activator 4 slight decreases the viability of HepG2 cells after 72 hours of treatment at 10-20 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	C2C12 myotubes, HepG2 and HuH-7 cells
Concentration:	0-20 μM
Incubation Time:	12-24 hours
Result:	Induced dose-dependently phosphorylation of ACC in C2C12 myotube cells, and the phosphorylation of ACC was highly consistent with the phosphorylation of AMPK. Increased the phosphorylation of AMPK and ACC in human hepatocarcinoma HepG2 and HuH-7 cells.

体内研究
(In Vivo)

AMPK activator 4 (100 mg/kg; Intragastrical administration; daily for 9 weeks) shows anti-hyperglycemic effect.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	db/db mice (5-week old)
Dosage:	100 mg/kg
Administration:	Intragastrical administration; daily for 9 weeks
Result:	Significantly lowered the fasting blood glucose in db/db mice (2-6 weeks). Significantly improved insulin resistance in db/db mice (for 9 weeks). The body weight and the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (two markers of liver injury) were not significantly affected.

体内研究

AMPK activator 4 (100 mg/kg; Intragastrical administration; daily for 9 weeks) shows anti-hyperglycemic effect.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	db/db mice (5-week old)
Dosage:	100 mg/kg
Administration:	Intragastrical administration; daily for 9 weeks
Result:	Significantly lowered the fasting blood glucose in db/db mice (2-6 weeks). Significantly improved insulin resistance in db/db mice (for 9 weeks). The body weight and the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (two markers of liver injury) were not significantly affected.

体内研究

AMPK activator 4 (100 mg/kg; Intragastrical administration; daily for 9 weeks) shows anti-hyperglycemic effect.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	db/db mice (5-week old)
Dosage:	100 mg/kg
Administration:	Intragastrical administration; daily for 9 weeks
Result:	Significantly lowered the fasting blood glucose in db/db mice (2-6 weeks). Significantly improved insulin resistance in db/db mice (for 9 weeks). The body weight and the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (two markers of liver injury) were not significantly affected.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (593.98 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3759 mL	11.8796 mL	23.7592 mL
5 mM	0.4752 mL	2.3759 mL	4.7518 mL
10 mM	0.2376 mL	1.1880 mL	2.3759 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.94 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.94 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。